Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017-2018

被引:29
作者
Deng, Yunlei [1 ]
Zhao, Qianwen [2 ]
Gong, Rong [1 ]
机构
[1] Chongqing Med Univ, Chengdu Affiliated Hosp 2, Peoples Hosp Chengdu 3, Dept Nephrol, 37 Qinglong St, Chengdu, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Gastroenterol & Hepatol, Chengdu, Peoples R China
来源
DIABETES METABOLIC SYNDROME AND OBESITY | 2021年 / 14卷
关键词
metabolic associated fatty liver disease; chronic kidney disease; diabetes mellitus; hyperuricemia; PREVALENCE; HYPERTENSION; RISK; CKD; MANAGEMENT; DIAGNOSIS; ADULTS; NAFLD;
D O I
10.2147/DMSO.S292926
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: In 2020, an international expert consensus proposed a novel concept, defined as metabolic associated fatty liver disease (MAFLD). We aimed to investigate the association between MAFLD and chronic kidney disease (CKD). Methods: A total of 4869 subjects with demographic data, laboratory tests, and ultrasound transient elastography from National Health and Nutrition Examination Surveys of the United States (NHANES) 2017-2018 were included in the study. Statistical analysis was performed to test the independent association between the demographic data, laboratory tests, and non-invasive liver fibrosis scores in subjects with different subgroups of MAFLD. Results: A total of 4869 subjects were identified in the NHANES 2017-2018, of which 1032 (21.2%) subjects were diagnosed with CKD. There was a higher prevalence of CKD in MAFLD subjects than in non-MALFD subjects (22.2% vs 19.1, p=0.048). After 1:1 propensity score matching by gender, age and race, we enrolled 1983 subjects with MAFLD diagnosed based on liver ultrasound transient elastography and 1983 PS-matched subjects without MAFLD. MAFLD was not independently associated with CKD after PSM. Further investigation showed that age (OR: 1.05, 95% CI: 1.03 similar to 1.05, p<0.001), hypertension (OR: 1.66, 95% CI: 1.38 similar to 2.00, p<0.001), DM (OR: 2.21, 95% CI: 1.89 similar to 3.11, p<0.001), hyperuricemia (OR: 1.91, 95% CI: 1.55 similar to 2.36, p<0.001), ALP (OR: 1.00, 95% CI: 1.00 similar to 1.01, p=0.010), and FIB-4 score (OR: 1.23, 95% CI: 1.05 similar to 1.01, p=0.011) were independently associated with CKD. In the subgroup analysis, the subgroups of MAFLD complicated with DM, age, hypertension, and hyperuricemia were independently related to the incidence of CKD. In the subgroup of DM without MAFLD, age, hyperuricemia, ALP, and NFS score were independently related to the incidence of CKD. In the subgroup of MAFLD without DM, age, hypertension, hyperuricemia, and ALP were independently related to the incidence of CKD. Conclusion: Based on the NHANES 2017-2018, MAFLD was not independently associated with CKD. Thus, the link between MAFLD and CKD may be mediated by metabolic abnormalities, such as diabetes mellitus and hyperuricemia.
引用
收藏
页码:1751 / 1761
页数:11
相关论文
共 37 条
[1]   Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study [J].
Akahane, Takemi ;
Akahane, Manabu ;
Namisaki, Tadashi ;
Kaji, Kosuke ;
Moriya, Kei ;
Kawaratani, Hideto ;
Takaya, Hiroaki ;
Sawada, Yasuhiko ;
Shimozato, Naotaka ;
Fujinaga, Yukihisa ;
Furukawa, Masanori ;
Kitagawa, Koh ;
Ozutsumi, Takahiro ;
Tsuji, Yuki ;
Kaya, Daisuke ;
Mitoro, Akira ;
Yoshiji, Hitoshi .
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (06)
[2]   Masked Hypertension in CKD: Increased Prevalence and Risk for Cardiovascular and Renal Events [J].
Babu, Megha ;
Drawz, Paul .
CURRENT CARDIOLOGY REPORTS, 2019, 21 (07)
[3]   Uric acid in CKD: has the jury come to the verdict? [J].
Bonino, Barbara ;
Leoncini, Giovanna ;
Russo, Elisa ;
Pontremoli, Roberto ;
Viazzi, Francesca .
JOURNAL OF NEPHROLOGY, 2020, 33 (04) :715-724
[4]   Changes in the US Burden of Chronic Kidney Disease From 2002 to 2016 An Analysis of the Global Burden of Disease Study [J].
Bowe, Benjamin ;
Xie, Yan ;
Li, Tingting ;
Mokdad, Ali H. ;
Xian, Hong ;
Yan, Yan ;
Maddukuri, Geetha ;
Al-Aly, Ziyad .
JAMA NETWORK OPEN, 2018, 1 (07) :e184412
[5]   NAFLD as a driver of chronic kidney disease [J].
Byrne, Christopher D. ;
Targher, Giovanni .
JOURNAL OF HEPATOLOGY, 2020, 72 (04) :785-801
[6]   The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases [J].
Chalasani, Naga ;
Younossi, Zobair ;
Lavine, Joel E. ;
Charlton, Michael ;
Cusi, Kenneth ;
Rinella, Mary ;
Harrison, Stephen A. ;
Brunt, Elizabeth M. ;
Sanyal, Arun J. .
HEPATOLOGY, 2018, 67 (01) :328-357
[7]   Noninvasive indices for predicting nonalcoholic fatty liver disease in patients with chronic kidney disease [J].
Choe, A. Reum ;
Ryu, Dong-Ryeol ;
Kim, Hwi Young ;
Lee, Hye Ah ;
Lim, Jiyoung ;
Kim, Jin Sil ;
Lee, Jeong Kyong ;
Kim, Tae Hun ;
Yoo, Kwon .
BMC NEPHROLOGY, 2020, 21 (01)
[8]   Uric acid and hypertension: a focused review and practical recommendations [J].
De Becker, Benjamin ;
Borghi, Claudio ;
Burnier, Michel ;
van de Borne, Philippe .
JOURNAL OF HYPERTENSION, 2019, 37 (05) :878-883
[9]  
EASL, 2016, OBESITY FACTS, V9, P65, DOI [10.1159/000443344, 10.1007/s00125-016-3902-y, 10.1016/j.jhep.2015.11.004]
[10]   Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review [J].
El Din, Usama A. A. Sharaf ;
Salem, Mona M. ;
Abdulazim, Dina O. .
JOURNAL OF ADVANCED RESEARCH, 2017, 8 (05) :537-548